173 related articles for article (PubMed ID: 35467009)
1. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
Gupta N; Largajolli A; Witjes H; Diderichsen PM; Zhang S; Hanley MJ; Lin J; Mehta M
Clin Pharmacol Ther; 2022 Aug; 112(2):327-334. PubMed ID: 35467009
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
4. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
5. Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer.
Gupta N; Pierrillas PB; Hanley MJ; Zhang S; Diderichsen PM
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):731-744. PubMed ID: 35316867
[TBL] [Abstract][Full Text] [Related]
6. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
[TBL] [Abstract][Full Text] [Related]
8. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
[TBL] [Abstract][Full Text] [Related]
9. Mobocertinib (TAK-788): A Targeted Inhibitor of
Gonzalvez F; Vincent S; Baker TE; Gould AE; Li S; Wardwell SD; Nadworny S; Ning Y; Zhang S; Huang WS; Hu Y; Li F; Greenfield MT; Zech SG; Das B; Narasimhan NI; Clackson T; Dalgarno D; Shakespeare WC; Fitzgerald M; Chouitar J; Griffin RJ; Liu S; Wong KK; Zhu X; Rivera VM
Cancer Discov; 2021 Jul; 11(7):1672-1687. PubMed ID: 33632773
[TBL] [Abstract][Full Text] [Related]
10. Mobocertinib in non-small cell lung cancer.
Liu S; Lowder KE
Drugs Today (Barc); 2022 Nov; 58(11):523-530. PubMed ID: 36422513
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Piotrowska Z; Tan DS; Smit EF; Spira AI; Soo RA; Nguyen D; Lee VH; Yang JC; Velcheti V; Wrangle JM; Socinski MA; Koczywas M; Janik JE; Jones J; Yu HA
J Clin Oncol; 2023 Sep; 41(26):4218-4225. PubMed ID: 37384848
[TBL] [Abstract][Full Text] [Related]
13. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for
Yang JC; Zhou C; Jänne PA; Ramalingam SS; Kim TM; Riely GJ; Spira AI; Piotrowska Z; Mekhail T; Garcia Campelo MR; Felip E; Bazhenova L; Jin S; Kaur M; Diderichsen PM; Gupta N; Bunn V; Lin J; N Churchill E; Mehta M; Nguyen D
Expert Rev Anticancer Ther; 2023 Jan; 23(1):95-106. PubMed ID: 36537204
[TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Duke ES; Stapleford L; Drezner N; Amatya AK; Mishra-Kalyani PS; Shen YL; Maxfield K; Zirkelbach JF; Bi Y; Liu J; Zhang X; Wang H; Yang Y; Zheng N; Reece K; Wearne E; Glen JJ; Ojofeitimi I; Scepura B; Nair A; Bikkavilli RK; Ghosh S; Philip R; Pazdur R; Beaver JA; Singh H; Donoghue M
Clin Cancer Res; 2023 Feb; 29(3):508-512. PubMed ID: 36112541
[TBL] [Abstract][Full Text] [Related]
15. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS; Li F; Gong Y; Zhang Y; Youngsaye W; Xu Y; Zhu X; Greenfield MT; Kohlmann A; Taslimi PM; Toms A; Zech SG; Zhou T; Das B; Jang HG; Tugnait M; Ye YE; Gonzalvez F; Baker TE; Nadworny S; Ning Y; Wardwell SD; Zhang S; Gould AE; Hu Y; Lane W; Skene RJ; Zou H; Clackson T; Narasimhan NI; Rivera VM; Dalgarno DC; Shakespeare WC
Bioorg Med Chem Lett; 2023 Jan; 80():129084. PubMed ID: 36423823
[TBL] [Abstract][Full Text] [Related]
16. New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
David GM; Maria Del Pilar BC; Cristina MR
J Oncol Pharm Pract; 2023 Jun; 29(4):934-943. PubMed ID: 36916182
[TBL] [Abstract][Full Text] [Related]
17. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Duan J; Wu L; Yang K; Zhao J; Zhao Y; Dai X; Li M; Xie Y; Yao Y; Zhao M; Zhou C; Ren X; Liu Z; Pan Y; Li Y; Liu B; Cheng Y; Miao L; Yu Q; Zhang Z; Liu X; Cui J; Zhang Y; Zhang L; Li X; Li X; Shen B; Chen B; Zeng S; Li B; Hu Y; Li L; Wu R; Song Q; Wang J
J Thorac Oncol; 2024 Feb; 19(2):314-324. PubMed ID: 37776953
[TBL] [Abstract][Full Text] [Related]
18. Mobocertinib: First Approval.
Markham A
Drugs; 2021 Nov; 81(17):2069-2074. PubMed ID: 34716908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
Ou SI; Prawitz T; Lin HM; Hong JL; Tan M; Proskorovsky I; Hernandez L; Jin S; Zhang P; Lin J; Patel J; Nguyen D; Neal JW
Clin Lung Cancer; 2024 May; 25(3):e145-e152.e3. PubMed ID: 38114357
[TBL] [Abstract][Full Text] [Related]
20. Targeting
Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
